Ian G Barr Selected Research

Zanamivir (Relenza)

1/2022	Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
1/2019	Circulation and characterization of seasonal influenza viruses in Cambodia, 2012-2015.
1/2015	Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring.
2/2013	Influenza antiviral resistance in the Asia-Pacific region during 2011.
9/2010	Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
10/2009	Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
9/2004	In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors.
7/2004	Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
4/2004	Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
1/2003	Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ian G Barr Research Topics

Disease

62	Human Influenza (Influenza) 04/2022 - 01/2003
25	Infections 01/2020 - 01/2005
3	COVID-19 04/2022 - 11/2021
2	Neoplasms (Cancer) 12/2021 - 02/2016
2	Influenza in Birds (Avian Flu) 02/2009 - 04/2008
1	Obesity 04/2022
1	Pain (Aches) 01/2021
1	Orthomyxoviridae Infections 01/2020
1	Virus Diseases (Viral Diseases) 02/2016
1	Body Weight (Weight, Body) 01/2015
1	Lung Diseases (Lung Disease) 05/2012
1	Coinfection 09/2010

Drug/Important Bio-Agent (IBA)

19	Neuraminidase (Sialidase)IBA 01/2022 - 01/2003
19	Oseltamivir (Tamiflu)FDA Link 01/2020 - 01/2003
18	VaccinesIBA 04/2022 - 10/2006
15	Influenza Vaccines (Influenza Vaccine)FDA Link 04/2022 - 01/2006
13	Antiviral Agents (Antivirals)IBA 01/2020 - 01/2005
10	Zanamivir (Relenza)FDA Link 01/2022 - 01/2003
9	Hemagglutinins (Hemagglutinin)IBA 01/2020 - 04/2008
6	Pharmaceutical PreparationsIBA 04/2022 - 09/2010
5	oseltamivir carboxylateIBA 01/2022 - 01/2003
4	AntibodiesIBA 01/2021 - 08/2010
3	peramivirIBA 01/2022 - 04/2008
3	AntigensIBA 01/2018 - 06/2007
3	EnzymesIBA 03/2013 - 07/2004
2	laninamivirIBA 01/2022 - 03/2014
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2020
2	CytokinesIBA 01/2018 - 01/2018
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2011 - 08/2010
1	Aligeron (AS 2)IBA 12/2021
1	Analgesics (Analgesic Drugs)IBA 01/2021
1	Respiratory Syncytial Virus VaccinesIBA 01/2021
1	NucleoproteinsIBA 01/2020
1	nitazoxanide (NTZ)FDA Link 01/2020
1	Messenger RNA (mRNA)IBA 01/2019
1	Biological ProductsIBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	ChemokinesIBA 01/2018
1	InterferonsIBA 01/2018
1	Glycoproteins (Glycoprotein)IBA 01/2018
1	Neutralizing AntibodiesIBA 01/2018
1	Matrix-MIBA 12/2017
1	Indicators and Reagents (Reagents)IBA 02/2016
1	EpitopesIBA 02/2015
1	AdamantaneIBA 02/2013
1	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 11/2011
1	Rimantadine FDA LinkGeneric 01/2009
1	Amino Acids FDA Link 01/2009
1	Amantadine (Aman)FDA LinkGeneric 01/2009
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2007
1	Nucleic AcidsIBA 11/2006
1	Peptide Hydrolases (Proteases)FDA Link 10/2006

Therapy/Procedure

4	Therapeutics 12/2021 - 01/2005
1	Hematopoietic Stem Cell Transplantation 12/2021
1	Analgesia 01/2021
1	Hand Hygiene 02/2009
1	Injections 04/2008
1	Length of Stay 06/2007